# Safety and Tolerability of hRPC in Retinitis Pigmentosa

> **NCT02464436** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ReNeuron Limited** · enrollment: 29 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** hRPC

## Key facts

- **NCT ID:** NCT02464436
- **Lead sponsor:** ReNeuron Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2022-06
- **Final completion:** 2023-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464436, "Safety and Tolerability of hRPC in Retinitis Pigmentosa". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02464436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*